Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development, as well as ABO-102 and ABO-101, novel AAV-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively, in Phase 1/2 development. The Company's portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical needs. Abeona's novel, next-generation AIM™ capsids have shown potential to improve tropism profiles for a variety of devastating diseases. Abeona's fully functional, gene and cell therapy GMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL™ study and is capable of clinical and commercial production of AAV-based gene therapies.
Company profile
Ticker
ABEO
Exchange
Website
CEO
Joao Siffert
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ACCESS PHARMACEUTICALS INC, CHEMEX PHARMACEUTICALS INC, PLASMATECH BIOPHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Abeona Therapeutics LLC • MacroChem Corporation ...
IRS number
830221517
ABEO stock data
Latest filings (excl ownership)
424B5
Prospectus supplement for primary offering
29 Mar 23
8-K
Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
29 Mar 23
10-K
2022 FY
Annual report
29 Mar 23
S-8
Registration of securities for employees
22 Mar 23
8-K
Regulation FD Disclosure
13 Mar 23
EFFECT
Notice of effectiveness
13 Dec 22
CORRESP
Correspondence with SEC
6 Dec 22
UPLOAD
Letter from SEC
5 Dec 22
S-3
Shelf registration
30 Nov 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
Transcripts
ABEO
Earnings call transcript
2022 Q1
17 May 22
ABEO
Earnings call transcript
2021 Q1
25 May 21
ABEO
Earnings call transcript
2020 Q4
25 Mar 21
ABEO
Earnings call transcript
2019 Q2
12 Aug 19
ABEO
Earnings call transcript
2019 Q1
14 May 19
ABEO
Earnings call transcript
2018 Q4
19 Mar 19
ABEO
Earnings call transcript
2018 Q3
12 Nov 18
ABEO
Earnings call transcript
2018 Q2
10 Aug 18
ABEO
Earnings call transcript
2018 Q1
14 May 18
ABEO
Earnings call transcript
2017 Q4
27 Mar 18
Latest ownership filings
4
Michael Amoroso
21 Mar 23
4
Joseph Walter Vazzano
17 Mar 23
4
Michael Amoroso
3 Mar 23
4
Brendan M. O'Malley
3 Mar 23
SC 13G
Nantahala Capital Management, LLC
14 Feb 23
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 23
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 23
SC 13G/A
Flynn James E
10 Feb 23
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
9 Feb 23
SC 13G/A
HIRSCHMAN ORIN
10 Jan 23
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 14.56 mm | 14.56 mm | 14.56 mm | 14.56 mm | 14.56 mm | 14.56 mm |
| Cash burn (monthly) | (no burn) | 2.02 mm | 4.31 mm | 4.24 mm | 4.66 mm | 3.62 mm |
| Cash used (since last report) | n/a | 6.10 mm | 13.01 mm | 12.80 mm | 14.08 mm | 10.94 mm |
| Cash remaining | n/a | 8.45 mm | 1.54 mm | 1.75 mm | 479.84 k | 3.62 mm |
| Runway (months of cash) | n/a | 4.2 | 0.4 | 0.4 | 0.1 | 1.0 |
Institutional ownership, Q4 2022
| 13F holders | Current |
|---|---|
| Total holders | 44 |
| Opened positions | 23 |
| Closed positions | 2 |
| Increased positions | 8 |
| Reduced positions | 6 |
| 13F shares | Current |
|---|---|
| Total value | 26.33 bn |
| Total shares | 21.92 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Sco Capital Partners | 11.36 mm | $15.68 mm |
| Flynn James E | 1.74 mm | $0.00 |
| Adage Capital Partners GP, L.L.C. | 1.33 mm | $4.10 bn |
| Point72 Asset Management | 1.15 mm | $3.54 bn |
| Armistice Capital | 1.11 mm | $3.41 bn |
| EcoR1 Capital | 1.09 mm | $3.35 bn |
| Deerfield Management | 869.57 k | $2.68 bn |
| Hirschman Orin | 652.17 k | $0.00 |
| AIGH Capital Management | 652.17 k | $2.01 bn |
| Vanguard | 292.53 k | $900.99 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 20 Mar 23 | Michael Amoroso | Common Stock | Sell | Dispose S | No | No | 2.33 | 268 | 624.44 | 56,441 |
| 15 Mar 23 | Vazzano Joseph Walter | Common stock | Payment of exercise | Dispose F | No | No | 2.6 | 792 | 2.06 k | 94,458 |
| 3 Mar 23 | Brendan M. O'Malley | Common stock | Payment of exercise | Dispose F | No | No | 2.28 | 207 | 471.96 | 93,623 |
| 3 Mar 23 | Michael Amoroso | Common Stock | Sell | Dispose S | No | No | 2.38 | 1,002 | 2.38 k | 56,709 |
| 9 Dec 22 | Brendan M. O'Malley | Common stock | Buy | Acquire P | No | No | 3.13 | 5,869 | 18.37 k | 93,830 |
News
Abeona Therapeutics Announces Acceptance Of Abstract On EB-101 Phase 3 VIITAL Study Results For Oral Presentation At International Societies For Investigative Dermatology 2023 Meeting
16 Mar 23
Abeona Therapeutics-Sponsored Trial: EB-101 Treatment for New and Previously Treated Patients With Recessive Dystrophic Epidermolysis Bullosa Posted To Clinical Trials Website; Study Not Yet Recruiting
13 Feb 23
Press releases
Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
29 Mar 23
Abeona Therapeutics Announces New Employee Inducement Grants
24 Mar 23
Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting
16 Mar 23
Abeona Therapeutics Announces Update on AAV Ophthalmology Program
14 Mar 23